Sic transl med:血小板通过调节髓系抑制因子加速动脉粥样硬化进展

2019-11-08 QQY MedSci原创

众所周知,血小板是止血和血栓形成的介质,但其炎症效应特性越来越多的被揭示出来。动脉粥样硬化,一种慢性血管炎性疾病,代表了动脉壁脂质沉积与未解决的炎症之间的相互作用。近期,研究人员发现血小板可诱导单核细胞迁移和招募到动脉粥样硬化斑块,导致斑块血小板-巨噬细胞聚集。在以西方膳食(高脂饮食)喂养的Ldlr-/-小鼠中,耗竭血小板可减小斑块的大小和坏死区,并可减少巨噬细胞积累。血小板通过使斑块巨噬细胞向炎

众所周知,血小板是止血和血栓形成的介质,但其炎症效应特性越来越多的被揭示出来。动脉粥样硬化,一种慢性血管炎性疾病,代表了动脉壁脂质沉积与未解决的炎症之间的相互作用。

近期,研究人员发现血小板可诱导单核细胞迁移和招募到动脉粥样硬化斑块,导致斑块血小板-巨噬细胞聚集。在以西方膳食(高脂饮食)喂养的Ldlr-/-小鼠中,耗竭血小板可减小斑块的大小和坏死区,并可减少巨噬细胞积累。

血小板通过使斑块巨噬细胞向炎症表型倾斜、增加细胞因子信号3 (SOCS3)的髓系抑制因子的表达和降低Socs1: SOCS3的比值来驱动动脉粥样硬化形成。血小板诱导的Socs3表达通过促进炎性细胞因子(Il6、Il1b和Tnfa)的产生和削弱吞噬细胞能力来调节斑块巨噬细胞的重编程,使其功能障碍进而导致未解决的炎症和持续的斑块生长。

在心血管疾病人类患者中,研究人员发现与无心肌梗死的女性相比,有心肌梗死的女性的SOCS3的表达上调、SOCS1:SOCS3比值减小、单核细胞-血小板聚集增多。一个关于下肢动脉硬化患者的次级队列表明,SOCS3和SOCS1:SOCS3比值与血小板活性和炎症相关。

总而言之,本研究揭示了血小板介导的髓系炎症和功能障碍、SOCS3和心血管疾病之间的因果关系,明确了血小板的促动脉粥样硬化作用,并强调了在没有血栓形成的情况下,血小板如何促进炎症。

原始出处:

Tessa J. Barrett, et al.Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis.Science Translational Medicine. 06 Nov 2019:Vol. 11, Issue 517, eaax0481. DOI: 10.1126/scitranslmed.aax0481

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822026, encodeId=779f182202641, content=<a href='/topic/show?id=e37a1021254c' target=_blank style='color:#2F92EE;'>#髓系抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102125, encryptionId=e37a1021254c, topicName=髓系抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Wed Feb 19 07:03:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944631, encodeId=49ba194463192, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Nov 21 15:03:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067468, encodeId=646f206e468ef, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Dec 07 16:03:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657250, encodeId=0514165e250c7, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Jun 22 09:03:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532096, encodeId=5ce9153209660, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610109, encodeId=09e5161010992, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822026, encodeId=779f182202641, content=<a href='/topic/show?id=e37a1021254c' target=_blank style='color:#2F92EE;'>#髓系抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102125, encryptionId=e37a1021254c, topicName=髓系抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Wed Feb 19 07:03:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944631, encodeId=49ba194463192, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Nov 21 15:03:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067468, encodeId=646f206e468ef, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Dec 07 16:03:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657250, encodeId=0514165e250c7, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Jun 22 09:03:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532096, encodeId=5ce9153209660, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610109, encodeId=09e5161010992, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822026, encodeId=779f182202641, content=<a href='/topic/show?id=e37a1021254c' target=_blank style='color:#2F92EE;'>#髓系抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102125, encryptionId=e37a1021254c, topicName=髓系抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Wed Feb 19 07:03:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944631, encodeId=49ba194463192, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Nov 21 15:03:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067468, encodeId=646f206e468ef, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Dec 07 16:03:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657250, encodeId=0514165e250c7, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Jun 22 09:03:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532096, encodeId=5ce9153209660, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610109, encodeId=09e5161010992, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1822026, encodeId=779f182202641, content=<a href='/topic/show?id=e37a1021254c' target=_blank style='color:#2F92EE;'>#髓系抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102125, encryptionId=e37a1021254c, topicName=髓系抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Wed Feb 19 07:03:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944631, encodeId=49ba194463192, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Nov 21 15:03:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067468, encodeId=646f206e468ef, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Dec 07 16:03:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657250, encodeId=0514165e250c7, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Jun 22 09:03:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532096, encodeId=5ce9153209660, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610109, encodeId=09e5161010992, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-06-22 bsmagic9140
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822026, encodeId=779f182202641, content=<a href='/topic/show?id=e37a1021254c' target=_blank style='color:#2F92EE;'>#髓系抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102125, encryptionId=e37a1021254c, topicName=髓系抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Wed Feb 19 07:03:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944631, encodeId=49ba194463192, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Nov 21 15:03:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067468, encodeId=646f206e468ef, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Dec 07 16:03:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657250, encodeId=0514165e250c7, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Jun 22 09:03:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532096, encodeId=5ce9153209660, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610109, encodeId=09e5161010992, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1822026, encodeId=779f182202641, content=<a href='/topic/show?id=e37a1021254c' target=_blank style='color:#2F92EE;'>#髓系抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102125, encryptionId=e37a1021254c, topicName=髓系抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Wed Feb 19 07:03:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944631, encodeId=49ba194463192, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Thu Nov 21 15:03:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067468, encodeId=646f206e468ef, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Dec 07 16:03:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657250, encodeId=0514165e250c7, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Jun 22 09:03:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532096, encodeId=5ce9153209660, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610109, encodeId=09e5161010992, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 10 06:03:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]

相关资讯

Blood:嗜酸性粒细胞-血小板互作促进动脉粥样硬化和血栓的形成

临床观察发现嗜酸性粒细胞活化的标志物在动脉粥样硬化和血栓形成中升高,因此推测提嗜酸性粒细胞在心血管疾病中具有一定作用。但嗜酸性粒细胞对动脉粥样硬化斑块形成和动脉血栓形成的作用仍不明确。Marx等人在这些背景下,来研究嗜酸性粒细胞是如何通过与血小板的相互作用被招募和激活的。研究人员为嗜酸性粒细胞-血小板相互作用在动脉粥样硬化和血栓形成中的重要作用提供了证据,证明了嗜酸性粒细胞参与内皮细胞上von W

Blood:缺铁促进巨核系-红系祖细胞(MEP)向巨核细胞系偏倚进展

缺铁性贫血患者血小板增多的机制尚不清楚。有这样一种假设,即低铁会促进巨核系-红系祖细胞(MEP)向巨核细胞(Mk)系偏倚进展。Xavier-Ferrucio等人在人和小鼠中证实了该假设。与野生型(WT)小鼠的MEP相比,在表现为缺铁性贫血和血小板增多症的特异性敲除跨膜丝氨酸蛋白酶6(Tmprss6-/-)小鼠的MEP中,研究人员观察到Mk偏倚、不稳定铁减少和增殖减少。骨髓移植实验显示是系统性铁缺乏

Blood:SHP2功能异常通过影响血小板的信号和功能导致努南综合征

SHP2,由PTPN11基因编码,是一种普遍存在的蛋白酪氨酸磷酸酶,是信号转导的关键调节因子。PTPN11基因的胚系突变导致SHP2的催化功能获得或丧失,分别可导致两种多器官缺陷的疾病:Noonan综合征(NS)和伴随多发雀斑的NS(NSML)。NS患者常发生出血异常,但病因尚不明确。本研究在NS/NSML患者中和携带导致这两种疾病的PTPN11突变的两种小鼠模型中研究血小板激活。NS小鼠和患者来

Blood:血小板板状伪足的形成不参与稳定血栓的形成

中心点:Cyfip1在肌动蛋白丝的分支和板状伪足的形成过程中起着至关重要的作用在形成止血栓或血栓时并不需要形成板状伪足摘要:在血小板扩散过程中,肌动蛋白细胞骨架发生快速重排,形成丝状伪足和板状伪足。板状伪足在血栓形成和稳定中的作用一直存在争议。在其他细胞中,通过Arp2/3复合物增强肌动蛋白核形成来驱动板状伪足的形成的WAVE调控复合物,被Rac1与WAVE复合物亚基Cyfip1的相互作用激活。S

Blood:血小板特异性抗体检测的新方法

在人体内,血小板膜糖蛋白多态性具有免疫原性,是引起新生儿同种免疫性血小板减少症等疾病的重要临床免疫反应的原因。来源于携带罕见多态性个体的血小板通常难以获得,使得诊断性检测和输注匹配的血小板具有挑战性。I类HLA抗体经常出现在母体血清中,对血小板反应性同种抗体的检测带来额外的干扰。检测人血小板抗原(HPA) 3和9的同种异体抗体尤其具有挑战性,部分原因是由于位于多态氨基酸附近的细胞类型特异性聚糖的存

Blood:血小板计数高于25x109/L时,给新生儿输注血小板反而会增加出血和死亡风险

新生儿血小板减少症输注血小板的试验(PlaNeT-2)显示,与以50x109/L为阈值相比,以25x109/L为预防大出血和(或)早产儿死亡的输注血小板的阈值获得了意想不到的总体效益(绝对风险降低7%)。但该试验中的部分新生儿可能从25x109/L阈值中获益甚少,甚至会受到伤害。